Foresite Capital Reveals 14.5% Stake in Alumis Following IPO
ALMS has more than doubled off its 52-week low of $3.76.
Summary
Foresite Capital disclosed a 14.5% stake in Alumis Inc. after the company's IPO, with shares acquired through preferred stock conversions and a $2.52M purchase at $18.00 per share.
Key Events · Ownership and Investor Activity · ALMS
-
Foresite Capital Holds 14.5% Stake
Following the IPO on August 10, 2026, Foresite entities beneficially own 9,181,328 shares, or 14.5% of the class, in Alumis Inc.
-
IPO Purchase of $2.52M
Fund VI purchased 140,000 shares at $18.00 per share from underwriters, totaling $2,520,000.
-
Preferred Stock Conversions
Series A-2 and Series B preferred shares converted to common stock at the IPO, contributing 9,041,328 shares to the total stake.
-
Convertible Note Conversion
A $3.5M convertible note issued to Fund VI in June 2026 converted into common stock at the IPO price.
Analysis · ALMS · Life Sciences
Following Alumis's August 10 IPO, Foresite Capital entities led by board member James Tananbaum hold 9.18 million shares, representing a 14.5% ownership stake. The position was built through pre-IPO preferred stock conversions and a $2.52 million purchase of 140,000 shares at $18.00 per share. A 180-day lock-up agreement prevents immediate selling, but the disclosure signals a major insider's long-term commitment and clarifies the post-IPO ownership structure.
At the time of this filing, ALMS was trading at $25.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $3.76 to $31.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.